Matsuda T, Miyata Y, Nakamura Y, et al. - In prostate cancer (PC), large tumor suppressor 2 (LATS2) acts as a tumor suppressor. LATS2 expression was found to be a beneficial predictor for biochemical recurrence (BCR). The results showed that LATS2-related activities are possibly dependent on the androgen-dependency of PC cells. The results imply that LATS2 could be a potential therapeutic target and a useful predictor for outcome in patients with PC.

• The results indicated that knockdown (KD) of LATS2 elevated the growth, migration, and invasion in LNCaP cells and only elevated migration in PC3 cells.

• The findings demonstrated that the expression of LATS2 was negatively correlated with the grade group, T, N, M stage, and PI.

• The outcomes indicated that the expression of LATS2 was a useful predictor of the histological effects of neoadjuvant hormonal therapy and BCR-free survival periods.

• As per the findings, a multivariate analysis model including clinicopathological features demonstrated that negative expression of LATS2 had a significantly higher risk of BCR (odds ratio = 2.95, P < 0.001).